Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
about
Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis.Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning.Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review.
P2860
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
@ast
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
@en
type
label
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
@ast
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
@en
prefLabel
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
@ast
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
@en
P2093
P2860
P1476
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
@en
P2093
Akbar K Waljee
Peter D R Higgins
Sameer D Saini
P2860
P304
P356
10.1016/J.CGH.2012.05.003
P407
P577
2012-05-18T00:00:00Z